当前位置 : 首页 > 市场合作 > 项目信息市场合作
Market cooperation| 发包方名称 | National University Corporation - Osaka |
| 发包方国别(国家/地区) | 日本 |
| 发包方座机 | |
| 发包方传真 | |
| 发包方邮箱 | |
| 发包方地址 | Procurement Section, Accounting Division, Osaka University Hospital, 2-15 Yamadaoka Suita shi Osaka 565-0871 Japan |
| 发包方网址 | |
| 发包方联系人姓名 | ISHII Kouji |
| 发包方联系人座机 | 06-6879-5134 |
| 发包方联系人手机 | |
| 发包方联系人邮箱 | |
| 项目名称 | Lenalidomide Hydrate (5㎎/1capsule 40capsules/1case) 300 cases,and 26 other contracts |
| 项目类型 | 其他 - 其他 |
| 项目预算￥ | |
| 项目投标截止时间 | 2022-03-10 |
| 项目开始时间 | |
| 项目结束时间 | |
| 服务商资质要求 | |
| 要求高匹配度成功案例个数 | |
| 项目交付地点 | |
| 是否准许转包或分包 | |
| 项目信息详述 |
⑴ Official in charge of disbursement of the procuring entity : NISHIO Shojiro, President, Osaka University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Lenalidomide Hydrate (5㎎/1capsule 40capsules/1case) 300 cases
B Pembrolizumab (Genetical Recombination) (100㎎4㎖/1vial) 1,000 vials
C Bevacizumab (Genetical Recombination) (100㎎4㎖/1vial) 1,780 vials
D Bevacizumab (Genetical Recombination) (400㎎16㎖/1vial) 1,540 vials
E Cetuximab (Genetical Recombination) (100㎎20㎖/1vial) 1,840 vials
F Ustekinumab (Genetical Recombination) (45㎎0.5㎖/1syringe) 380 syringes
G Rituximab (Genetical Recombination) (500㎎50㎖/1vial) 440 vials
H Agalsidase Alfa (Genetical Recombination) (3.5㎎3.5㎖/1vial) 180 vials
I Infliximab (Genetical Recombination) (100㎎/1vial) 2,940 vials
J Palonosetron Hydrochloride (0.75㎎
5㎖/1vial 5vials/1case) 920 cases
K Paclitaxel (100㎎/1vial) 2,380 vials
L Pertuzumab (Genetical Recombination) (420㎎14㎖/1vial) 600 vials
M Romiplostim (Genetical Recombination) (250㎍/1vial) 820 vials
N Eculizumab (Genetical Recombination) (300㎎30㎖/1vial) 600 vials
O Panitumumab (Genetical Recombination) (100㎎5㎖/1vial) 560 vials
P Denosumab (Genetical Recombination) (120㎎1.7㎖/1vial) 1,940 vials
Q Pegfilgrastim (Genetical Recombination) (3.6㎎0.36㎖/1syringe) 820 syringes
R Ramucirumab (Genetical Recombination) (500㎎50㎖/1vial) 160 vials
S Nusinersen Sodium (12㎎5㎖/1vial) 8 vials
T Nivolumab (Genetical Recombination) (240㎎24㎖/1vial) 1,280 vials
U Elapegademase (2.4㎎1.5㎖/1vial) 100 vials
V Emicizumab (Genetical Recombination) (150㎎1.0㎖/1vial) 80 vials
W Patisiran Sodium (8.8㎎4.4㎖/1vial) 160 vials
X Tisagenlecleucel 8 Sets
Y Aflibercept (Genetical Recombination) (2㎎0.05㎖/1syringe) 5,560 syringes
Z Pabinafusp Alfa (Genetical Recombination) (12.5㎎/1vial) 420 vials
AA lisocabtagene maraleucel 1 Set
⑷ Delivery period : By 1 April, 2022 through 31 March, 2023
⑸ Delivery place : Osaka University Hospital and Dental Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 7 and 8 of the Regulation concerning the Contract for Osaka University,
B have the Grade A or Grade B qualification during fiscal 2022 in the Kinki area in sales of product for participating in tenders by Single qualification for every ministry and agency, or in tenders by Osaka University,
C prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices.
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by President.
⑺ Time limit of tender : 12 : 00 10 March, 2022
⑻ Contact point for the notice : ISHII Kouji, Procurement Section, Accounting Division, Osaka University Hospital, 2-15 Yamadaoka Suita shi Osaka 565-0871 Japan, TEL 06-6879-5134
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.
|
版权所有：天津市数字贸易综合服务平台 备案号：津B2-20080229-9
联系人：高杨 
手机：+86-131-1480-9286 
邮箱：gloria.gao@devott.com 
微信：13114809286 
